ADMA Biologics Faces Class Action Over Alleged Securities Violations

The complaint filed against the NASDAQ-listed company claims violations of the Securities Exchange Act of 1934. According to the legal filing, ADMA allegedly failed to disclose a significant related-party transaction and engaged in channel stuffing to artificially inflate its reported sales activity. These actions reportedly rendered the company's public disclosures during the class period materially misleading.

Shareholders who incurred losses due to these discrepancies have until August 10, 2026, to seek lead plaintiff status. While the DJS Law Group is actively soliciting participants, the firm notes that appointment as a lead plaintiff is not a prerequisite for recovering potential damages. The case remains focused on addressing the impact of these alleged misrepresentations on investor value.